Trials / Recruiting
RecruitingNCT06330012
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Accepted
Summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | GeoMx data analysis with clinical outcome | 1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome |
Timeline
- Start date
- 2024-03-18
- Primary completion
- 2025-01-15
- Completion
- 2027-12-31
- First posted
- 2024-03-26
- Last updated
- 2024-03-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06330012. Inclusion in this directory is not an endorsement.